Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 5:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: XIAFLEX Clear all
Completed Phase 1 Interventional

The Safety, Effectiveness, and Pharmacokinetics of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)

NCT01518907
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy, Cellulite
Interventions
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
21 Years to 60 Years · Female only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Sep 11, 2026, 5:35 PM EDT
Completed No phase listed Observational

CORRECT: COmmunity RegistRy Study Evaluating Dupuytren's Contracture Treatment

NCT01715467
View directory record Official record
Conditions
Dupuytren's Contracture
Interventions
Not listed
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
27
States / cities
Burbank, California • Encinitas, California • La Jolla, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2015 · Synced Sep 11, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease

NCT00528840
View directory record Official record
Conditions
Advanced Dupuytren's Disease
Interventions
collagenase clostridium histolyticum
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
14
States / cities
Phoenix, Arizona • Tucson, Arizona • Burbank, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2017 · Synced Sep 11, 2026, 5:35 PM EDT
Completed No phase listed Observational

Long-term Durability Study of Collagenase Clostridium Histolyticum (CCH)

NCT04381117
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy
Interventions
Previously Treated with EN3835
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Clearwater, Florida • Coral Gables, Florida • Washington, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Sep 11, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Results available

AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease

NCT00528424
View directory record Official record
Conditions
Advanced Dupuytren's Disease
Interventions
AA4500
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
15
States / cities
Los Angeles, California • Palo Alto, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2017 · Synced Sep 11, 2026, 5:35 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Delayed Manipulation After Xiaflex Treatment in Subjects With Dupuytren's Contracture

NCT01226121
View directory record Official record
Conditions
Dupuytren's Disease
Interventions
Clostridial collagenase injectable
Biological
Lead sponsor
Indiana Hand to Shoulder Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
2
States / cities
Indianaplis, Indiana • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2014 · Synced Sep 11, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease

NCT01430169
View directory record Official record
Conditions
Peyronie's Disease
Interventions
AA4500
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Burbank, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 11, 2026, 5:35 PM EDT
Not yet recruiting Early Phase 1 Interventional

Collagenase Injection for Contracture Management

NCT07693556
View directory record Official record
Conditions
Contracture
Interventions
Active XIAFLEX Collagenase injection
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 11, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effectiveness and Safety of EN3835 in the Treatment of EFP (Cellulite) in Women

NCT03428750
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy (Cellulite)
Interventions
EN3835, Placebo
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
423 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
26
States / cities
Scottsdale, Arizona • Encinitas, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Sep 11, 2026, 5:35 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of Xiaflex Injection for Treatment of Dupuytren's Contracture of the Thumb

NCT01265420
View directory record Official record
Conditions
Dupuytren's Contracture
Interventions
Injectable clostridial collagenase
Biological
Lead sponsor
Indiana Hand to Shoulder Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Indianaplis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Sep 11, 2026, 5:35 PM EDT
Not yet recruiting Early Phase 1 Interventional

Collagenase Injection for Spasticity Management

NCT07693569
View directory record Official record
Conditions
Spasticity
Interventions
XIAFLEX Collagenase injection
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 11, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2, Randomized, Double-blind, Placebo Controlled Dose Ranging Study of Repeat Doses of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy

NCT01987986
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy (EFP)
Interventions
Collagenase Clostridium Histolyticum, Placebo
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
10
States / cities
San Diego, California • Santa Monica, California • Coral Gables, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 11, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Results available

Clinical Study for the Treatment of Adhesive Capsulitis of the Shoulder

NCT02006719
View directory record Official record
Conditions
Adhesive Capsulitis, Frozen Shoulder
Interventions
Collagenase Clostridium Histolyticum, Placebo
Biological · Other
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
35
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 11, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)

NCT02724644
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy, Cellulite
Interventions
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM, Placebo Comparator
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
16
States / cities
Beverly Hills, California • Murrieta, California • Oceanside, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 11, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Two Concurrent Injections of AA4500 in Adult Subjects With Multiple Dupuytren's Contractures

NCT01674634
View directory record Official record
Conditions
Dupuytren's Contracture
Interventions
XIAFLEX / XIAPEX
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
715 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
25
States / cities
Phoenix, Arizona • Tucson, Arizona • Encinitas, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 11, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Results available

AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder

NCT01483963
View directory record Official record
Conditions
Adhesive Capsulitis, Frozen Shoulder
Interventions
AA4500 0.29 mg/1 mL, AA4500 0.58 mg/2 mL, AA4500 0.58 mg/1 mL, AA4500 0.58 mg/0.5 mL, Shoulder exercises
Biological · Other
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 11, 2026, 5:35 PM EDT
Withdrawn Not applicable Interventional

Focused Shock Wave Therapy Outcomes in Peyronie's Disease and Erectile Dysfunction

NCT05646602
View directory record Official record
Conditions
Peyronie Disease, Penile Curvature, Erectile Dysfunction
Interventions
Collagenase Clostridium Histolyticum, Duolith SD1 T-TOP
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Sep 11, 2026, 5:35 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Investigation of Surgery, Collagenase, and Restorex for the Improvement of Peyronie's

NCT04786106
View directory record Official record
Conditions
Peyronie's Disease
Interventions
Collagenase Clostridium Histolyticum 0.9 MG [Xiaflex] (CCH), Penile Plication Surgery, Incision and Grafting (I&G) Surgery, RestoreX Penile Traction Device
Drug · Procedure · Device
Lead sponsor
Charitable Union for the Research and Education of Peyronie's Disease
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Orem, Utah
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 11, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Results available

Study of AA4500 in the Treatment of Peyronie's Disease

NCT01221597
View directory record Official record
Conditions
Peyronie's Disease
Interventions
AA4500, Placebo
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
29
States / cities
Homewood, Alabama • Phoenix, Arizona • Burbank, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 11, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Results available

Study of AA4500 in the Treatment of Peyronie's Disease

NCT01221623
View directory record Official record
Conditions
Peyronie's Disease
Interventions
AA4500, Placebo
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
29
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 11, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Results available

Collagenase in the Treatment of Dupuytrens Disease

NCT00260429
View directory record Official record
Conditions
Dupuytren's Disease
Interventions
collagenase clostridium histolyticum
Biological
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Dec 8, 2010 · Synced Sep 11, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Injection Techniques of Collagenase Clostridium Histolyticum (CCH) for the Treatment of EFP (Cellulite)

NCT03632993
View directory record Official record
Conditions
Edematous Skin
Interventions
collagenase clostridium histolyticum (CCH)
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
5
States / cities
Coral Gables, Florida • Miami, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Sep 11, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Results available

AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Dupuytren's Contracture

NCT00528606
View directory record Official record
Conditions
Dupuytren's Contracture
Interventions
collagenase clostridium histolyticum, Placebo
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
15
States / cities
Los Angeles, California • Palo Alto, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2017 · Synced Sep 11, 2026, 5:35 PM EDT
Completed No phase listed Observational

Treatment Response to Xiaflex for Men With Peyronie's Disease

NCT03774264
View directory record Official record
Conditions
Peyronie Disease
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Sep 11, 2026, 5:35 PM EDT